envveno.com - NVNO Profit before deduction of interest, taxes, depreciation and amortization
The stable management of NVNO effectively optimizes R&D costs, earning the market's trust. The team attracts leading bioengineers through stock option programs and a modern laboratory infrastructure. Quarterly EBITDA confirms financial maturity, where the value of 0.00 reflects this status. This enables enVVeno Medical to successfully implement innovative valve bioprostheses in collaboration with specialized surgeons and clinical centers.
Summary analytical data breakdowns for enVVeno Corp (NVNO)
- stock value and consensus price forecast:
- issuer market value details:
- book capitalization indicators:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio enVVeno Medical|NVNO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio enVVeno|NVNO - Company Aggregate Debts|Debts to Book Value enVVeno Medical Corp.|NVNO - Company Long-Term Debts|Company Short-Term Indebtedness enVVeno Medical|Interim Coverage Ratio envveno.com
- earnings and market multiples details:
NVNO - Net Profit|Future Profit enVVeno Medical|NVNO - P/E Multiple|Forward P/E Multiple enVVeno Medical Corporation|NVNO - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization enVVeno|NVNO - Operating profit before deduction of amortization|Earnings per share for the trailing year enVVeno Medical|NVNO - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months envveno.com|NVNO - Earnings per share growth in current year|Net earnings per one share growth forecast for next year enVVeno Medical
- sales revenue and business income indicators:
Summary company analytics:enVVeno Medical
This indicator measures daily cash flow from core operations minus operating expenses, allowing for an assessment of the business's actual ability to service debt under tight monetary policy. An analysis of quarterly EBITDA for enVVeno Medical (NVNO) reveals financial stability during the final stages of VenoValve clinical trials, which is critical for valuing the company ahead of potential M&A transactions.
Who enVVeno Medical competes with
BSX (Boston Scientific) - Profit before deduction of interest, taxes, depreciation and amortization|Edwards Lifesciences Corp - Operating profit EBITDA|Profit before interest, taxes and amortization ResMed|PODD: Operating profit EBITDA|Operating profit before amortization ZBH|Operating profit before deduction of amortization COO|Operating profit before amortization ALGN (Align Technology)|Operating profit before deduction of amortization GMED (Globus Medical)|TMDX (TransMedics Corp) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Alphatec Corp ATEC|AORT - Operating profit before deduction of amortization|Enovis Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Integra LifeSciences|ESTA: Operating profit EBITDA|Operating profit before amortization BBNX|IRMD (IRADIMED Inc.) - Operating profit EBITDA|Embecta Inc. (EMBC) - Operating income before deduction of amortization|Operating profit EBITDA TNDM|Operating profit before deduction of amortization AxoGen, Inc. AXGN|Operating profit EBITDA SIBN (si-bone.com)|Operating profit EBITDA Orthofix Medical OFIX|BVS: Operating profit before deduction of amortization|KIDS: Profit before payment of interest, taxes and amortization|TMCI (Treace Medical Concepts) - Operating profit before deduction of amortization|Strata Critical Medical Inc - Income before deduction of interest, taxes and amortization|CARL (Carlsmed Medical) - Operating profit EBITDA|Profit before interest, taxes and amortization RxSight Inc RXST|Profit before payment of interest, taxes and amortization ClearPoint Neuro (CLPT)|Stereotaxis, Inc. (STXS) - Operating profit before depreciation charges|Neuronetics, Inc - Operating profit before deduction of amortization|Operating profit EBITDA Sight Sciences, Inc. SGHT|Orchestra BioMed Inc. - Operating profit EBITDA|Operating income before deduction of amortization Anika Therapeutics, Inc. ANIK|InspireMD (NSPR) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization ZJYL (Jin Medical International Ltd)|Profit before payment of interest, taxes and amortization vivani.com|Operating profit before deduction of amortization Xtant Medical Holdings (XTNT)|Operating profit EBITDA NMTC|MODD - Profit before interest, taxes and amortization|Myomo - Operating profit before deduction of amortization|COCH: Operating profit before amortization|VVOS: Operating profit before deduction of amortization|Sintx Technologies, Inc. - Company profit before taxes, interest and amortization|TNON (Tenon Medical, Inc.) - Operating profit before deduction of amortization|Lifeward - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization AMIX|Profit before payment of interest, taxes and amortization IVF|Profit before payment of interest, taxes and amortization Bone Biologics Corp (BBLG)|AXNX - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization BIOLASE BIOL|Operating profit EBITDA dynatronics.com DYNT|FNA - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization INVO (invobioscience.com)
